U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
September 12, 2022 at 09:15 AM EDT
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application ...